Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema

Abstract

Clinical signs should be assessed in all atopic eczema trials by at least the Eczema Area and Severity Index. Quality of life, symptoms, and flares should also be assessed in all atopic eczema trials by a valid, reliable, and feasible instrument.

Quality of life and disease severity in patients with atopic dermatitis

“…Scoring of AD (SCORAD), comprised of objective signs of disease (disease extent and intensity), and subjective short‐term symptoms (pruritus and sleep loss), is a commonly used severity index in AD (range: 0–103 points with a high score indicating severe disease) . SCORAD was assessed by a staff nurse.…”

“…Scoring of AD (SCORAD), 13 comprised of objective signs of disease (disease extent and intensity), and subjective short-term symptoms (pruritus and sleep loss), 14 is a commonly used severity index in AD (range: 0-103 points with a high score indicating severe disease). 15,16 SCORAD was assessed by a staff nurse. QoL was evaluated using translated Danish editions 17 of the dermatology life quality index (DLQI) for patients aged 16 years and above and the Children's dermatology life quality index (CDLQI) 18 for patients aged 4-15 years.…”

Measurement properties of adult quality‐of‐life measurement instruments for eczema: a systematic review

“…Clinicians and researchers should include a QoL measurement instrument in every future eczema trial because QoL is one of the core outcome domains of the proposed COS. As no instrument for measuring adult QoL in eczema trials can be highly recommended at the moment, the HOME initiative suggests using any QoL instrument that is at least valid, reliable and feasible in eczema patients . Unfortunately, we found in our review that currently no such instrument is available.…”

Experimental models of atopic dermatitis for preclinical researches

“…Рабочая группа Harmonizing Outcomes Measures for Eczema (HOME) определила такие признаки, как экскориация, эритема, отек/образование папул и лихенификация, минимальными клиническими симптомами, которые следует оценивать в доклинических испытаниях на моделях АтД [12]. Эритема и отек/образование папул характерны для острых стадий заболевания, в то время как экскориации и лихенификация наблюдаются при хроническом процессе [7].…”